Boston Partners Sells 211,740 Shares of PAREXEL International Co. (PRXL)
Boston Partners reduced its stake in PAREXEL International Co. (NASDAQ:PRXL) by 32.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 437,043 shares of the medical research company’s stock after selling 211,740 shares during the period. Boston Partners owned 0.86% of PAREXEL International worth $38,495,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. IndexIQ Advisors LLC bought a new position in shares of PAREXEL International in the 3rd quarter worth $8,986,000. Gabelli Funds LLC raised its stake in PAREXEL International by 373.7% during the 3rd quarter. Gabelli Funds LLC now owns 320,992 shares of the medical research company’s stock worth $28,273,000 after buying an additional 253,224 shares during the period. State of Wisconsin Investment Board raised its stake in PAREXEL International by 86.2% during the 3rd quarter. State of Wisconsin Investment Board now owns 124,500 shares of the medical research company’s stock worth $10,966,000 after buying an additional 57,653 shares during the period. BT Investment Management Ltd raised its stake in PAREXEL International by 152.4% during the 3rd quarter. BT Investment Management Ltd now owns 9,110 shares of the medical research company’s stock worth $802,000 after buying an additional 5,500 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its stake in PAREXEL International by 10.4% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 39,173 shares of the medical research company’s stock worth $3,450,000 after buying an additional 3,690 shares during the period. Institutional investors and hedge funds own 87.45% of the company’s stock.
Shares of PAREXEL International Co. (NASDAQ:PRXL) opened at $88.08 on Monday. PAREXEL International Co. has a 12 month low of $51.16 and a 12 month high of $88.10. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.45 and a current ratio of 1.45.
PAREXEL International (NASDAQ:PRXL) last released its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.94 by $0.08. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. The firm had revenue of $557.20 million for the quarter, compared to the consensus estimate of $537.59 million. During the same quarter last year, the business posted $0.94 EPS.
Several analysts recently commented on PRXL shares. Zacks Investment Research raised PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 price objective on the stock in a research note on Thursday, August 31st. BidaskClub downgraded PAREXEL International from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $78.68.
WARNING: “Boston Partners Sells 211,740 Shares of PAREXEL International Co. (PRXL)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/boston-partners-sells-211740-shares-of-parexel-international-co-prxl/1699869.html.
About PAREXEL International
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.